Thymosin alpha-1 inhibited NSCLC growth by promoting myeloid-derived suppressor cell apoptosis and blocking their migration to tumors through HIF-1α/VEGF suppression.
VEGF suppressionthymosin alpha-1 reduces tumor VEGF production via HIF-1α, cutting off MDSC recruitment signals
What the researchers found
Thymosin alpha-1 promoted M-MDSC apoptosis by reducing Bcl-2/BAX ratio and inhibited MDSC migration to tumors by suppressing HIF-1α-mediated VEGF production in tumor cells.
Why it matters
Thymosin alpha-1 is already approved in many countries as an immune modulator. Understanding that it works against cancer partly by blocking MDSC recruitment provides rationale for combining it with immunotherapy drugs like checkpoint inhibitors.
The numbers in context
TA1 reduced M-MDSCs in patient blood and decreased MDSC accumulation and VEGF in mouse tumors.
How the study worked
Studies on peripheral blood M-MDSCs from NSCLC patients. Mouse subcutaneous xenograft tumor model. qRT-PCR, Western blotting, flow cytometry, and immunohistochemistry to examine mechanisms.
Who was studied
NSCLC patients (blood samples) and mouse tumor models
What this study cannot tell us
Xenograft models don't fully recapitulate human tumor immunology. The specific doses and timing for optimal MDSC suppression in humans need determination. Clinical trial data for Tα1 as an anti-cancer agent in NSCLC is limited.
How to read the evidence
Combined human patient samples and animal model evidence with clear mechanistic pathway. Pre-clinical but uses an already-approved peptide drug.
When this study was published
Published in 2020. Thymosin alpha-1 in combination with immunotherapy continues to be explored in clinical settings.
The bigger picture
The tumor immune microenvironment is a major focus of cancer research. MDSCs are key contributors to immune evasion, and finding that an approved peptide drug can reduce their accumulation opens combination therapy possibilities with existing immunotherapies.
Questions still open
- Would combining thymosin alpha-1 with checkpoint inhibitors like anti-PD-1 enhance anti-tumor responses in NSCLC?
- Does Tα1's MDSC suppression extend to other solid tumor types?
- What is the optimal dosing schedule for Tα1 to maximize tumor microenvironment remodeling?
Common questions
What are myeloid-derived suppressor cells?
Is thymosin alpha-1 already used in medicine?
Read the original research
Thymosin alpha-1 blocks the accumulation of myeloid suppressor cells in NSCLC by inhibiting VEGF production.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 131, 110740
Citation
Yang, Zhenzhen; Guo, Jiacheng; Cui, Kang; Du, Yabing; Zhao, Huan; Zhu, Lili; Weng, Lanling; Tang, Wenxue; Guo, Jiancheng; Zhang, Tengfei; Shi, Xiaojing; Zong, Hong; Jin, Shuiling; Ma, Wang. (2020). Thymosin alpha-1 blocks the accumulation of myeloid suppressor cells in NSCLC by inhibiting VEGF production.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 131, 110740. https://doi.org/10.1016/j.biopha.2020.110740